UK markets closed

Regencell Bioscience Holdings Limited (RGC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
17.98-0.66 (-3.54%)
At close: 4:00PM EDT
18.00 +0.02 (+0.11%)
After hours: 05:35PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close18.64
Open18.54
Bid18.00 x 1000
Ask18.30 x 3000
Day's range17.98 - 19.71
52-week range6.00 - 59.00
Volume28,558
Avg. volume807,218
Market cap227.359M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.09
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • The Independent

    Cineworld to pay £122m to dissenting shareholders after Regal takeover

    The original acquisition of Regal was a deal worth around £2.7 billion, or around 23 US dollars per share, in 2017.

  • Reuters

    Cineworld pays $170 million to Regal investors unhappy with 2017 buyout

    According to an agreement, $92 million will be held in escrow and be available to Cineworld as additional liquidity under certain circumstances for the payment, Cineworld said on Friday. Cineworld included $244.2 million in its last annual report, which it said represented the amount payable to a group of Regal's former stakeholders who had challenged whether they received a fair market price for their shares. The company had said the claim was without merit, backing the $23 per Regal share it paid for the $3.6 billion purchase that positioned it as a top competitor to U.S.-listed AMC Entertainment Holdings Inc.

  • Business Wire

    Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment

    HONG KONG, September 02, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), today announced that Regencell Bioscience Limited ("Regencell HK"), the Company’s wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises Limited ("Honor Epic"). The joint venture ("JV") is expected to offer COVID-19 ("COVID") related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.